Skip to main content

Saturday, July 20:  All UR Medicine facilities are open as scheduled and providing safe patient care, with a goal to return all clinical services to full efficiency by early next week.
Patients: click here for more information. Faculty/Staff: click here for information.


Human Papillomavirus Vaccine Impact Monitoring Project


The Human Papillomavirus (HPV) Vaccine Impact Project (HPV-IMPACT), part of the Centers for Disease Control and Prevention Emerging Infections Program (EIP) is an ongoing surveillance project that monitors the impact of HPV vaccine on HPV types associated with cervical cancer and cervical cancer precursors. HPV-IMPACT determines rates of high-grade cervical lesions in women in the United States. 

Goals and Objectives

  • HPV VirusDescribe the incidence of HPV-associated high-grade cervical lesions and cervical cancer over time.
  • Obtain diagnostic biopsy specimens on all reported cases of high-grade cervical lesions in females 18 to 39 years of age in Monroe County.
  • Obtain additional detailed information on all reported cases of high-grade cervical lesions in females 18 to 39 years of age in Monroe County, including HPV vaccination history, complete demographic information and relevant medical history.
  • Describe cervical cancer screening utilization among females 18 to 39 years to monitor trends over time using methodology other than self-report.


The pathology laboratories in our catchment area continue to identify all cases of high-grade cervical lesions and cervical cancer in women 18 years of age and older. Lists are generated at each lab every month, using anatomic site language to capture all possible cases. Using a combination of administrative data and medical records, complete case information is collected. This includes: patient demographics, health insurance information, ordering provider and submitting pathologist contact information, cervical pathology information related to the current diagnosis, and detailed information relevant to women aged 18 to 39 years as outlined above.

Women aged 18 to 39 have a cervical pathology specimen selected for highest grade associated with that infection by the designated lab pathologist, retrieved, prepared and submitted to the CDC for histopathologic review and HPV typing.